Case report: Metastatic urothelial cancer with an exceptional response to immunotherapy and comprehensive understanding of the tumor and the tumor microenvironment

Although immune checkpoint inhibitors (ICIs) are increasingly used as second-line treatments for urothelial cancer (UC), only a small proportion of patients respond. Therefore, understanding the mechanisms of response to ICIs is critical to improve clinical outcomes for UC patients. The tumor microe...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Cora N. Sternberg, Nara Shin, Konstantin Chernyshov, Fabio Calabro, Linda Cerbone, Giuseppe Procopio, Natalia Miheecheva, Georgy Sagaradze, Alisa Zaichikova, Naira Samarina, Alexandra Boyko, Jessica H. Brown, Leysan Yunusova, Daniela Guevara, Jyothi Manohar, Michael Sigouros, Majd Al Assaad, Olivier Elemento, Juan Miguel Mosquera
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2022-10-01
Colecção:	Frontiers in Oncology
Assuntos:	urothelial cancer bladder cancer pembrolizumab KEYNOTE-045 trial tumor microenvironment whole-exome sequencing
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fonc.2022.1006017/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!